然而,除了常见的EML4-ALK融合外,各类ALK-TKI对于一些罕见的ALK融合突变,如STRN-ALK和HIP1-ALK等的疗效资料目前尚不完善[3]。孙立伟教授提到的两例患者虽然都存在ALK融合突变,但二者的突变亚型却是较为罕见的PRKAR1A-ALK与SPTBN1-ALK。面对这样的难题,环湖医院头颈神经肿瘤中心的专家团队陷入了抉择,究竟使用化疗、放...
然而,除了常见的EML4-ALK融合外,各类ALK-TKI对于一些罕见的ALK融合突变,如STRN-ALK和HIP1-ALK等的疗效资料目前尚不完善[3]。孙立伟教授提到的两例患者虽然都存在ALK融合突变,但二者的突变亚型却是较为罕见的PRKAR1A-ALK与SPTBN1-ALK...
ALK-SPTBN1基因重排在肠癌中仅有个案报道,这是一个新的融合伴侣,ALK抑制剂为最佳治疗选择。文献报道,存在ALK融合的肠癌的中位生存期仅为15个月,属于不良的预后因素 。 SMAD4为抑癌基因,SMAD4 Y434*为无义突变,导致SMAD4功能失活。 SMAD4基因突变--肠癌中一个不容忽视的基因突变,有关SMAD4基因的介绍可以参阅...
SPTBN1-ALKc-MetHER-2CrizotinibChemotherapyRadiotherapyCrizotinib is a multi-targeted tyrosine kinase inhibitor (TKI) with activity against mesenchymal-epithelial transition factor (MET) and anaplastic lymphoma kinase (ALK). However, the concomitant oncogenic drivers may affect the sensitivity of crizotinib....
Therefore, c-Met overexpression,HER-2gene amplification, andSPTBN1-ALK gene fusion can coexist in lung adenocarcinoma and may become a potential biomarker of cancer refractory to crizotinib, chemotherapy, and radiotherapy as well as of a relatively poor prognosis. In addition, the novelSPTBN1-ALK ...
A novel fusion gene SPTBN1-ALK.Jianming, YingChen, LinJian, WuLei, GuoTian, QiuYun, LingLing, ShanHaitao, ZhouDongbing, ZhaoJian, Wang